Skip to main content

Edoardo Caronna

Institutions of which they are part

Postdoctoral researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Edoardo Caronna

Institutions of which they are part

Postdoctoral researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Projects

Cefalea i dolor neurològic

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez, Nara Ikumi Montserrat, Marta Vila Pueyo, Erika Ivanna Araya, Edoardo Caronna
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00406
Duration: 01/01/2022 - 30/06/2025

Fenotipado molecular de pacientes con migrañA según edad y Sexo a través de la cuanTificación de CGRP en saliva para realizar medicina de precisión: estudio FAST.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Laura Gómez Dabó, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI22/01501
Duration: 01/01/2023 - 31/12/2026

Cefaleas y síndromes post-traumatismo craneoencefálico

IP: Patricia Pozo Rosich
Collaborators: Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM20/00217
Duration: 01/01/2021 - 31/12/2022

AhEAD: Algoritmo de predicción de Eficacia de respuesta A tratamiento preventivo en pacientes con migraña crónica: marcaDores biológicos y clínicos

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI19/01684
Duration: 01/01/2020 - 30/06/2024

Related news

On April 18 and 19, the Vall d’Hebron Research Institute (VHIR) will once again join the Science Festival 2026 with a diverse and participatory program focused on health, innovation, and citizen engagement in research.

The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Nunzio Gennaro Cifariello

Nunzio Gennaro Cifariello

Cap d'Unitat
Business Development Unit
Directorate of Innovation and Business Development
Read more
Antía Ferreiro Posse

Antía Ferreiro Posse

Senior researcher
Pneumology
Read more
Rafael Oleo Taltavull

Rafael Oleo Taltavull

Main researcher
Reconstructive Surgery of the Locomotor System
Read more
Juan Manuel Porras Paradas

Juan Manuel Porras Paradas

Research assistant
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.